drugset / Trial / NCT01873495

Omacetaxine for Consolidation and Maintenance

NCT01873495

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this pilot study is to assess the safety and tolerability of omacetaxine for consolidation in patients age 55 and older with acute myelogenous leukemia (AML) in first complete remission following induction with cytarabine and an anthracycline, and also to assess the safety and tolerability of omacetaxine for maintenance in patients age 55 and older with acute AML in first complete remission following 3 consolidation courses with omacetaxine.

Timeline

Start
2013-05
Primary completion
2018-07
Completion
2018-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Omacetaxine Unknown 1.25 mg/m2 Subcutaneous